1 An antibody-drug conjugate (ADC), ARX517 is comprised of a fully humanized anti–prostate-specific membrane antigen (PSMA) monoclonal antibody that is linked to AS269. After the product binds to PSMA on the surface of cancer cells, the drug is internalized and its payload,...
No serious adverse events or dose-limiting toxicities were observed in the phase 1/2 trial of the antibody drug conjugate ARX517. Prostate cancer under the microscope: © heitipaves - stock.adobe.com ARX517, an anti-prostate specific membrane antigen (PSMA) antibody dru...
AntibodySystem由具有30多年蛋白抗体开发经验的专家创立于法国,专注于生命科学和生物制药领域研究,总部位于法国斯特拉斯堡市。AntibodySystem自主开发了高效、高产的真核重组表达系统,利用该系统生产了高质量的重组蛋白、抗体产品。目前产品包括药物靶点蛋白以及对照抗体药物、Invivo功能性抗体、SAA系列流式抗体、PEG抗体、磷酸...
Ambrx首席执行官丹尼尔·奥康纳补充说:“这一快速通道称号对Ambrx来说是一个重要的里程碑。在我们扩展的遗传密码位点特异性偶联技术的支持下,ARX517 有可能成为这些患者更有效、更耐受的治疗选择,我们计划在今年秋天的一次大型医学会议上公布来自 APEX-01 的最新初步数据。” ARX517 is an antibody-drug conjugate comp...
ARX517’s site-specific linkage, stable conjugation chemistry, and non-cleavable linker exhibit a homogenous drug-antibody-ratio, mAb-like biophysical properties, and exceptional stability. Therefore, we believe ARX517 can promote highly...
ARX517 is composed of a humanized anti-PSMA antibody site-specifically conjugated to drug linker AS269 (a potent tubulin inhibitor), yielding a drug-to-antibody ratio of 2. After binding to PSMA expressed on the surface of tumor cells, ARX517 is internalized and delivers a cytotoxic payload ...
Poster Title:Preclinical characterization of ARX305, a next-generation anti-CD70 antibody drug conjugate for the treatment of CD70-expressing cancers Published Abstract Number:6318 Key Highlights: In a renal cell carcinoma (RCC, 786-OS3) xenograph model, ARX305 dose-depend...
John Shen, MD, medical oncologist, University of California Los Angeles Health Encino Cancer Care, discusses the utility of the prostate-specific membrane antigen (PSMA)–directed antibody-drug conjugate (ADC) ARX517 in patients with metastatic castration-resistant prostate cancer (mCRPC), highlighting...
(ADCs) and other engineered therapies to modulate the immune system. Ambrx is advancing a focused portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) ...
41P Evaluation of ARX517: A next-generation anti-PSMA antibody drug conjugate for prostate cancer treatment, in preclinical enzalutamide-resistant and enzalutamide-sensitive pharmacology models and in toxicology modelsdoi:10.1016/j.annonc.2023.09.1543S. Zhang...